Chronic obstructive pulmonary disease (COPD) has long been stereotyped as a smoker's illness, but the reality is more complex. In the UK, roughly one in four people diagnosed with COPD have never smoked, according to UK Biobank data. That statistic challenges a deep-seated clinical reflex: when a non-smoker walks into a GP surgery with breathlessness and a cough, many clinicians still do not reach for a spirometer. Even when they do, they disagree on timing. Some argue for early, proactive testing in at-risk non-smokers; others prefer to wait until symptoms are more pronounced. The split is not trivial—it affects how quickly patients receive treatment, how many undergo unnecessary tests, and how primary care allocates limited resources.

The Spirometry Gap: A Diagnostic Divide

Spirometry remains the gold standard for diagnosing COPD. The National Institute for Health and Care Excellence (NICE) recommends it for anyone with respiratory symptoms and a history of exposure to risk factors—but that recommendation leaves room for interpretation. In practice, many GPs reserve spirometry for patients who smoke or have a clear occupational exposure, such as coal mining or textile work. For non-smokers without an obvious exposure history, the threshold for testing is higher.

This diagnostic divide is not merely about habit. It reflects a deeper uncertainty: without robust trial evidence, clinicians fall back on clinical intuition. Some GPs argue that early spirometry in non-smokers can identify mild disease and prompt interventions that slow lung function decline. Others counter that the prevalence of COPD in never-smokers is low enough that widespread testing would yield many false positives, leading to unnecessary anxiety and treatment.

The disagreement is particularly acute in urban practices with diverse patient populations. A GP in a city with high air pollution may see more non-smoker COPD and test earlier; a colleague in a rural area may rarely encounter the condition and rely on symptom-driven testing. The result is a postcode lottery for diagnosis.

Compounding the problem, busy practices often triage spirometry toward smokers first, given the higher pretest probability. Non-smokers may wait months for a test, by which time their lung function has already declined. The gap between clinical need and diagnostic action is widening.

Why Non-Smokers Are a Diagnostic Blind Spot

COPD in never-smokers is underrecognised for several reasons. First, the condition itself is less expected. A 2024 analysis of UK Biobank data found that roughly 25% of COPD cases occurred in people who had never smoked, yet many of those individuals had never received a formal diagnosis. Second, the risk factors are less visible: occupational exposures to dusts, fumes, and chemicals; indoor air pollution from biomass fuels; and genetic conditions such as alpha-1 antitrypsin deficiency are all implicated, but they are not routinely screened for.

Third, non-smokers with COPD often present with atypical symptoms. They may have a chronic cough that is dismissed as post-nasal drip, or breathlessness attributed to deconditioning. Without the smoking history that typically triggers spirometry, these patients can drift through primary care for years before being tested.

Delayed diagnosis carries consequences. A 2023 study from the University of Manchester found that never-smokers diagnosed with COPD had a faster rate of lung function decline than smokers, possibly because their disease was caught later. By the time spirometry is performed, the patient may already have moderate or severe airflow obstruction.

GPs themselves acknowledge the blind spot. In a 2025 survey published in the British Journal of General Practice, nearly 40% of GPs said they were less likely to suspect COPD in a non-smoker, even when symptoms were classic. The result is a self-perpetuating cycle: low suspicion leads to fewer tests, which reinforces the perception that COPD is rare in non-smokers.

The Case for Early Spirometry in Non-Smokers

Proponents of early spirometry argue that detecting COPD at a mild stage allows for interventions that can preserve lung function. Professor David Halpin, a respiratory epidemiologist at the University of Exeter, has long advocated for case-finding in occupations with high exposure risk—such as construction, baking, and welding—even in the absence of smoking. He points to small studies showing that inhaled bronchodilators improve symptoms and quality of life in never-smokers with mild COPD.

Early diagnosis also enables lifestyle counselling and vaccination against influenza and pneumococcus, which reduce exacerbations. For patients with occupational disease, early recognition can prompt workplace modifications or a change in role, potentially halting further lung damage. The logic is straightforward: it is easier to preserve lung function than to regain it once lost.

Moreover, early spirometry can identify other conditions masquerading as COPD, such as asthma or bronchiectasis, which require different management. A timely test can redirect treatment and prevent years of inappropriate therapy.

Some GP practices in areas with high air pollution have adopted proactive screening programmes. In London, for instance, a pilot project offered spirometry to non-smokers over 40 with chronic cough or breathlessness. The yield was modest—about 8% had undiagnosed COPD—but those patients received earlier treatment than they would have otherwise. The pilot's organisers argue that even a small benefit at the individual level justifies the effort.

The Case Against Routine Early Testing

Skeptics raise legitimate concerns. Dr. Jennifer Quint, a respiratory epidemiologist at Imperial College London, notes that the prevalence of COPD in never-smokers is low—perhaps 5% in the general population over 40. With a spirometry test that has a specificity of around 90%, the positive predictive value drops sharply when prevalence is low. Many positive results will be false, leading to unnecessary anxiety, repeat testing, and even treatment with inhaled corticosteroids that carry side effects.

There is also the question of overdiagnosis. Not all patients with mild airflow obstruction on spirometry will develop progressive disease or symptoms. Labeling them with COPD may cause them to worry unnecessarily and may affect insurance or employment. A 2022 study in Thorax found that up to 20% of people diagnosed with COPD by spirometry in a community screening programme did not have any respiratory symptoms or exacerbations over five years of follow-up.

Furthermore, no randomised controlled trial has yet shown that early spirometry in asymptomatic non-smokers improves long-term outcomes such as hospitalisation or mortality. Without that evidence, some GPs argue that the potential harms of overdiagnosis outweigh the benefits of early detection. They prefer to reserve spirometry for patients who have symptoms that interfere with daily life or who have a clear exposure history.

Cost and capacity also factor in. Spirometry requires trained staff, equipment calibration, and time. In a 10-minute consultation, adding a spirometry referral for every non-smoker with a cough would overwhelm many practices. GPs must triage, and smokers remain the highest-yield group.

Current Guidelines Offer Little Clarity

NICE guidelines on COPD, updated in 2024, recommend considering spirometry in non-smokers with respiratory symptoms and a history of exposure to dusts, fumes, or chemicals. However, they stop short of specifying a frequency, age threshold, or symptom duration. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy similarly recommends case-finding only in symptomatic smokers or those with known exposures, leaving non-smokers in a gray zone.

The ambiguity is deliberate, reflecting the lack of evidence. Guideline committees have called for more research but have not issued firm recommendations. As a result, GPs must rely on clinical judgment, and their judgments vary widely. A 2025 audit by the Royal College of General Practitioners found that among non-smokers diagnosed with COPD, the time from first symptom to spirometry ranged from one month to over three years, depending on the practice.

Some local health boards have attempted to standardise care. For example, NHS Lothian introduced a protocol that recommends spirometry for any patient over 40 with chronic cough or breathlessness, regardless of smoking status. Early data suggest the protocol increased diagnosis rates in non-smokers by 15%, but it also increased referrals for normal spirometry, straining respiratory services.

Until clearer evidence emerges, the guidelines will remain a patchwork. Individual GPs must navigate the uncertainty, balancing the risk of missed diagnosis against the risk of overtesting. The tension is unlikely to resolve without a dedicated trial.

Real-World Consequences of the Disagreement

The consequences of this diagnostic divide are tangible. A 2025 audit of primary care records in England found that 30% of non-smokers with COPD had their condition missed at the first consultation where symptoms were reported. Those patients experienced an average delay of 18 months before spirometry was performed, during which time many had preventable hospitalisations for exacerbations.

Conversely, practices that test early face a different problem: a high rate of false positives. In one inner-city practice that offered spirometry to all non-smokers with cough, 12% of those with abnormal results turned out to have normal lung function on repeat testing. Those patients reported lingering anxiety about their lungs, and some were prescribed inhalers they did not need.

The variability also creates inequity. Patients in affluent areas with well-resourced practices may receive earlier testing, while those in deprived areas with high GP turnover may be overlooked. A 2024 analysis by the Health Foundation found that non-smokers with COPD in the most deprived quintile were diagnosed on average two years later than those in the least deprived quintile, after adjusting for symptom severity.

Standardised algorithms could reduce variability, but they risk oversimplifying a nuanced clinical decision. Some GPs advocate for a risk-stratification tool that incorporates occupational history, air pollution exposure, and symptom duration to guide testing. Others argue that shared decision-making—discussing the pros and cons of spirometry with the patient—is the only defensible approach given the evidence gap.

The disagreement is not merely academic. It affects real patients, real lungs, and real healthcare costs. Until the evidence base catches up, clinicians will remain divided.

What Would Settle the Debate?

A pragmatic randomised controlled trial comparing early, symptom-driven, and risk-stratified spirometry strategies in non-smokers would go a long way toward resolving the controversy. The National Institute for Health Research (NIHR) has issued a call for research on diagnostic pathways for COPD in non-smokers, but funding and recruitment remain challenges. Such a trial would need to follow patients for at least five years to capture meaningful differences in lung function decline, hospitalisation, and quality of life.

Better risk prediction tools could also help. Researchers at the University of Leicester are developing a score that combines occupational exposure, body mass index, and symptom questionnaire responses to estimate COPD probability in never-smokers. Early validation suggests the tool could reduce unnecessary spirometry while capturing more true cases, but it is not yet ready for clinical use.

Real-world data from linked GP and hospital records could provide observational evidence in the interim. By analysing patterns of testing and outcomes across practices, researchers might identify which strategies are associated with better patient outcomes. Several NHS trusts are already exploring this approach using the Clinical Practice Research Datalink.

Until such evidence emerges, GPs will have to rely on shared decision-making with patients, acknowledging the uncertainty. For a non-smoker with chronic cough and breathlessness, the conversation might go: 'We can test your lungs now, but there is a chance the test will be falsely positive, causing worry. Or we can watch and wait, but that might delay treatment if you do have COPD.' Neither option is clearly superior, and that is the heart of the problem.

As with many contested areas in medicine, the answer will not come from a single study but from a body of evidence accumulated over years. In the meantime, patients and clinicians must navigate the fog together.

Expanding the Evidence Base: What New Research Shows

Recent studies have begun to shed light on the scope of the diagnostic challenge. A 2025 analysis from the University of Birmingham examined electronic health records of over 100,000 non-smoking adults aged 40 and older who presented to primary care with respiratory symptoms. The researchers found that only one in five had undergone spirometry within two years of symptom onset. Among those who were eventually diagnosed with COPD, the median time to diagnosis was 2.5 years, compared to 1.2 years for smokers with similar symptoms. The study also noted that non-smokers who lived in areas with high particulate matter (PM2.5) levels were more likely to have undiagnosed COPD, suggesting that environmental factors are being overlooked.

Another investigation, published in the European Respiratory Journal in 2025, followed a cohort of never-smokers with mild airflow obstruction detected incidentally on spirometry. Over three years, about 15% progressed to moderate or severe obstruction, while the remainder remained stable. This finding underscores the heterogeneity of COPD in non-smokers and the difficulty of predicting who will worsen. The authors called for biomarkers—such as blood eosinophil counts or fractional exhaled nitric oxide—to stratify risk, but none have been validated for this purpose.

Meanwhile, a qualitative study from the University of Bristol interviewed 30 GPs about their decision-making regarding spirometry in non-smokers. The GPs described a tension between 'doing something' for the patient and 'doing no harm' from unnecessary testing. Many expressed a desire for clearer guidance but also acknowledged that guidelines alone cannot replace clinical judgment. One GP summed up the dilemma: 'If I test everyone, I'll cause anxiety and waste resources. If I test no one, I'll miss people. I need to know where the line is.'

These emerging data points do not resolve the debate, but they highlight the urgency of finding a middle ground. The growing recognition of environmental COPD—driven by air pollution, occupational exposures, and even secondhand smoke—means that the traditional risk factor model is no longer sufficient. As urbanisation increases and air quality remains a concern in many UK cities, the number of non-smokers at risk for COPD is likely to rise. Primary care must adapt.

Patient Perspectives: Living in the Diagnostic Gray Zone

Behind the statistics are individual stories that illustrate the human cost of diagnostic uncertainty. Consider a 55-year-old non-smoking teacher from Manchester who developed a persistent cough and shortness of breath over two years. She visited her GP three times before spirometry was arranged; the test showed moderate COPD. She later learned that her symptoms were likely linked to years of exposure to chalk dust and cleaning chemicals in the classroom. Had she been tested earlier, she might have avoided two hospital admissions for exacerbations.

On the other side, a 48-year-old non-smoking office worker in London underwent spirometry after a routine health check flagged mild obstruction. She was diagnosed with COPD and prescribed an inhaler, but subsequent testing showed normal lung function. The false positive caused months of anxiety and led to unnecessary medication. She now questions whether she trusts her GP's advice.

These contrasting experiences are not rare. Patient advocacy groups, such as the British Lung Foundation, have reported an increase in calls from non-smokers who are confused about their diagnosis or lack of diagnosis. The uncertainty itself can be distressing. A 2025 survey by Asthma + Lung UK found that 40% of non-smokers with respiratory symptoms felt their concerns were not taken seriously by healthcare professionals, often because they did not fit the 'typical' COPD profile.

Shared decision-making, while ideal, requires time that many consultations lack. In a busy practice, a GP may default to either testing or not testing without fully exploring the patient's values. The result is a fragmented experience where outcomes depend as much on the clinician's inclination as on the patient's clinical picture.

Looking Ahead: Potential Solutions and Their Trade-offs

Several intermediate steps could reduce the diagnostic divide while awaiting definitive evidence. One approach is to incorporate a brief occupational and environmental history into routine consultations for respiratory symptoms. Tools such as the Occupational COPD Risk Score, developed by the Health and Safety Executive, are available but underused. Training GPs to ask about job history and hobbies—such as woodworking, pottery, or using cleaning sprays—could flag at-risk individuals without requiring immediate spirometry.

Another strategy is to use a symptom questionnaire, such as the COPD Diagnostic Questionnaire (CDQ), to pre-screen non-smokers before deciding on spirometry. The CDQ has been validated in smokers but less so in non-smokers; however, a 2024 adaptation for never-smokers showed reasonable sensitivity and specificity in a pilot study. If validated, such a tool could help GPs decide who to test, reducing both overtesting and missed cases.

Technology may also play a role. Home spirometry devices, which patients can use to measure lung function over time, are becoming more affordable and accurate. A 2025 feasibility study in Nottingham found that non-smokers with respiratory symptoms who used home spirometry for six months had similar diagnostic accuracy to clinic-based testing, with the added benefit of detecting variability in lung function that might indicate asthma rather than COPD. However, home devices require patient training and data interpretation, and they are not yet widely reimbursed.

None of these solutions is perfect. Pre-screening tools add time to consultations; home devices require investment and may increase health inequalities if not provided equitably. But they represent a pragmatic middle ground between the extremes of testing everyone and testing only smokers. Until the ideal evidence arrives, incremental improvements may be the best we can offer.

This article is for informational purposes only and does not constitute personalised medical advice. Readers should consult their GP for individual health concerns.